Literature DB >> 27162798

Sense and sensibility to early combine bevacizumab to radiation treatment of brain metastasis: reply to Lou and Sperduto.

Christelle Lévy1, Audrey Emmanuelle Dugué1, Bénédicte Clarisse1.   

Abstract

Entities:  

Year:  2016        PMID： 27162798      PMCID： PMC4842403          DOI： 10.21037/atm.2016.03.41

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  8 in total

1.  Hypofractionated stereotactic radiosurgery with concurrent bevacizumab for recurrent malignant gliomas: the University of Alabama at Birmingham experience.

Authors:  Grant M Clark; Andrew M McDonald; Louis B Nabors; Hassan Fathalla-Shaykh; Xiaosi Han; Christopher D Willey; James M Markert; Barton L Guthrie; Markus Bredel; John B Fiveash
Journal:  Neurooncol Pract       Date:  2014-12

2.  Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.

Authors:  Kyle C Cuneo; James J Vredenburgh; John H Sampson; David A Reardon; Annick Desjardins; Katherine B Peters; Henry S Friedman; Christopher G Willett; John P Kirkpatrick
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-04-12       Impact factor: 7.038

3.  REBECA: a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours.

Authors:  C Lévy; D Allouache; J Lacroix; A E Dugué; S Supiot; M Campone; M Mahe; S Kichou; M Leheurteur; C Hanzen; V Dieras; Y Kirova; F Campana; E Le Rhun; L Gras; T Bachelot; M-P Sunyach; I Hrab; J Geffrelot; K Gunzer; J-M Constans; J-M Grellard; B Clarisse; X Paoletti
Journal:  Ann Oncol       Date:  2014-10-01       Impact factor: 32.976

4.  Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.

Authors:  Olivier L Chinot; Wolfgang Wick; Warren Mason; Roger Henriksson; Frank Saran; Ryo Nishikawa; Antoine F Carpentier; Khe Hoang-Xuan; Petr Kavan; Dana Cernea; Alba A Brandes; Magalie Hilton; Lauren Abrey; Timothy Cloughesy
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

5.  A randomized trial of bevacizumab for newly diagnosed glioblastoma.

Authors:  Mark R Gilbert; James J Dignam; Terri S Armstrong; Jeffrey S Wefel; Deborah T Blumenthal; Michael A Vogelbaum; Howard Colman; Arnab Chakravarti; Stephanie Pugh; Minhee Won; Robert Jeraj; Paul D Brown; Kurt A Jaeckle; David Schiff; Volker W Stieber; David G Brachman; Maria Werner-Wasik; Ivo W Tremont-Lukats; Erik P Sulman; Kenneth D Aldape; Walter J Curran; Minesh P Mehta
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

6.  Integrating bevacizumab and radiation treatment of brain metastasis: is there sense and sensibility in this approach?

Authors:  Emil Lou; Paul W Sperduto
Journal:  Ann Transl Med       Date:  2016-01

7.  Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial.

Authors:  Alvin R Cabrera; Kyle C Cuneo; Annick Desjardins; John H Sampson; Frances McSherry; James E Herndon; Katherine B Peters; Karen Allen; Jenny K Hoang; Zheng Chang; Oana Craciunescu; James J Vredenburgh; Henry S Friedman; John P Kirkpatrick
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-05-29       Impact factor: 7.038

8.  Salvage Fractionated Stereotactic Radiotherapy with or without Chemotherapy and Immunotherapy for Recurrent Glioblastoma Multiforme: A Single Institution Experience.

Authors:  Shaakir Hasan; Eda Chen; Rachelle Lanciano; Jun Yang; Alex Hanlon; John Lamond; Stephen Arrigo; William Ding; Michael Mikhail; Arezoo Ghaneie; Luther Brady
Journal:  Front Oncol       Date:  2015-05-15       Impact factor: 6.244
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.